Author + information
- Aditya A. Joshi,
- Amit Dey,
- Abhishek Chaturvedi,
- Jonathan Chung,
- Joshua Rivers,
- Mohammad Tarek Kabbany,
- Mark Ahlman,
- Martin Playford and
- Nehal Mehta
Background: Psoriasis (PSO), a chronic inflammatory disease associated with increased CV risk, provides a human model to study atherogenesis. While PSO is associated with increased vascular inflammation (VI), and impaired cholesterol efflux (CEC), the longitudinal impact of change in CEC on VI is unclear. We hypothesized that improvement in CEC may associate with reduction in VI.
Methods: 115 PSO patients underwent cardiometabolic profiling, FDG PET/CT scans to quantify VI as target-to-background ratio (TBR), at baseline and 1-year. CEC was measured using published, standardized methods. We stratified the cohort by improvement in CEC, analyzed longitudinal change in TBR and CEC with multivariable regression.
Results: Patients had low CV risk by Framingham risk (Median 3) and moderate PSO. 51 patients had improvement in CEC (mean +20%, p<0.001), while 64 had reduction (mean -13%, p<0.001) (Table 1). Though TBR improved in both groups, it was significant only in the group with improved CEC (1.73±0.05 vs. 1.61±0.03; p=0.002). Finally, TBR reduction associated with increase in CEC (β=-0.13, p=0.03) beyond traditional risk, BMI, statins and PSO treatment.
Conclusions: Improvement in CEC associated with reduction in aortic VI in PSO. Based on published studies, the 20% increase in CEC translates into roughly 24% CV risk reduction. Our findings suggest that improvement in reverse cholesterol transport may reduce VI, and thereby may mitigate future CV risk. Larger studies are needed to confirm our findings.
Poster Hall, Hall C
Friday, March 17, 2017, 10:00 a.m.-10:45 a.m.
Session Title: Vascular Medicine: New Insights Into Aortic and Peripheral Artery Diseases
Abstract Category: 40. Vascular Medicine: Non Coronary Arterial Disease
Presentation Number: 1128-357
- 2017 American College of Cardiology Foundation